原著論文（2018年～）
The use of concomitant medications on nephrotoxicity associated with teicoplanin:
A retrospective observational study.
J Infect Chemother. 2024:S1341-321X(24)00243-5.
Shimizu Y, Hanada K, Watanabe T, Sasaki Y, Yamazaki T, Komasaka E, Kadota
K.
Pharmacokinetics of anti-Mycobacterium avium-intracellulare disease drugs
in silkworms.
Sci Rep. 2024;14(1):16931.
Watanabe F, Matsumoto Y, Sugita T, Morishige Y, Mitarai S, Hoshino Y, Hanada
K.
Clofazimine serum concentration and safety/efficacy in nontuberculous mycobacterial
pulmonary disease treatment.
Respir Med. 2024;231:107718.
Watanabe F, Fujiwara K, Furuuchi K, Ito M, Hanada K, Kodama T, Aono A,
Mitarai S, Yoshiyama T, Kurashima A, Ohta K, Morimoto K.
Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine
([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL):
A study protocol.
PLoS One. 2024;19(5):e0303623.
Kobayakawa M, Shiga T, Takahashi K, Sugawara S, Nomura K, Hanada K, Ishizuka
N, Ito H.
Assessing clinical outcomes of vancomycin treatment in adult patients with
vancomycin-susceptible Enterococcus faecium bacteremia.
Antibiotics (Basel). 2023;12(11):1577.
Sasano H, Hanada K.
Physiologically based pharmacokinetic modeling of ponatinib to describe
drug-drug interactions in patients with cancer.
Cancer Chemother Pharmacol. 2022 ;90(4):315-323.
Morita TO, Hanada K.
Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of
Pulmonary Non-Tuberculous Mycobacterial Infection.
Antimicrob Agents Chemother. 2022 ;66(8):e0044122.
Watanabe F, Furuuchi K, Hanada K, Fujiwara K, Uesugi F, Hiramatsu M, Yoshiyama
T, Shiraishi Y, Kurashima A, Ohta K, Morimoto K.
Genome-wide analysis identify novel germline genetic variations in ADCY1
influencing platinum-based chemotherapy response in non-small cell lung
cancer.
Acta Pharm Sin B. 2022 ;12(3):1514-1522.
Mao C, Chen J, Zou T, Zhou Y, Liu J, Li X, Li X, Li M, Pan P, Zhuo W, Gao
Y, Hu S, Xiao D, Wu L, Wang Z, Xu H, Yang W, Xu Y, Xiao H, Hanada K, Zhang
W, Zhou H, Yin J, Liu Z.
Population Pharmacokinetic Model of Amiodarone and N-Desethylamiodarone
Focusing on Glucocorticoid and Inflammation.
Biol Pharm Bull. 2022;45(7):948-954.
Hirai T, Kasai H, Takahashi M, Uchida S, Akai N, Hanada K, Itoh T, Iwamoto
T.
Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical
outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare
disease: a retrospective cohort study.
Infection. 2022 ;50(4):879-887.
Watanabe F, Kaburaki S, Furuuchi K, Uesugi F, Fujiwara K, Tanaka Y, Yoshiyama
T, Shiraishi Y, Kurashima A, Ohta K, Hanada K, Morimoto K.
A simultaneous quantitative LC/MS method for determination of five anti-Mycobacterium
avium complex (MAC) disease drug in human plasma.
Jpn J Ther Drug Monit. 2022, 39(1):17-24.
Watanabe F, Morimoto K, Hanada K.
Involvement of the effect of renal hypoperfusion medications on vancomycin
trough concentration: A secondary analysis using a retrospective observational
data.
Basic Clin Pharmacol Toxicol.2021 ;129(5):376-384.
Hirai T, Hanada K, Iwamoto T, Itoh T
Effect of high-dose sulfamethoxazole/trimethoprim and glucocorticoid use
on hyperkalemic event: A retrospective observational study.
J Infect Chemother. 2021 ;27(11):1607-1613.
Hirai T, Yamaga R, Ishikawa Y, Hanada K, Iwamoto T, Itoh T
Impact of concomitant medication on clinical outcomes in patients with
advanced non‐small cell lung cancer treated with immune checkpoint inhibitors:
A retrospective study.
Thoracic Cancer 2021 ;12(13):1983-1994.
Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke
Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K
Population pharmacokinetic analysis and dose regimen optimization in Japanese
infants with an extremely low birth weight.
Antimicrob Agents Chemother. 2021;65:e02523-20.
Sasano H, Aoki K, Arakawa R, Hanada K
Population pharmacokinetics and renal toxicity of cisplatin in cancer patients
with renal dysfunction.
Cancer Chemother Pharmacol. 2020;86(4):559-566.
Morita OT, Sugita H, Minami H, Yamaguchi T, Hanada K
Effects of overweight and underweight on the treatment outcomes of rheumatoid
arthritis patients treated with biological drugs: a retrospective observational
descriptive study.
J Clin Pharm Ther. 2020;45(4):666-673.
Hirai T, Funaki A, Murakami K, Hanada K, Itoh T
Minocycline prevents and repairs the skin disorder associated with afatinib,
one of the epidermal growth factor receptor-tyrosine kinase inhibitors
for non-small cell lung cancer.
BMC Cancer 2020;20(1):279.
Sano K, Nakadate K, Hanada K
Renin-angiotensin system inhibitors for countering proteinuria inducedby
angiogenesis inhibitors: a retrospective observational analysis.
Cancer Chemother Pharmacol. 2019;84(1):195-202.
Hirai T, Shuji Y, Takiyama M, Hanada K, Itoh T.
新薬開発時に行われる母集団薬物動態解析結果と臨床薬物動態試験解析結果の乖離
臨床薬理 2019; 50(3):89-95.
花田和彦、元村あゆみ、緒方宏泰
Impact of Q141K on the transport of epidermal growth factor receptor tyrosinekinase
inhibitors by ABCG2.
Cells. 2019;8(7):763.
Inoue Y, Morita T, Onozuka M, Saito KI, Sano K, Hanada K, Kondo M, NakamuraY,
Kishino T, Nakagawa H, Ikegami Y.
Risk factors for vancomycin nephrotoxicity and time course of renal function
during vancomycin treatment.
Eur J Clin Pharmacol. 2019;75(6):859-866.
Hirai T, Hanada K, Kanno A, Akashi M, Itoh T.
抗がん剤のジェネリック医薬品の普及状況
臨床医薬 2018; 34(12):849-853.
杉本修治, 今井康人, 飯島肇, 菅野彩夏, 高橋みのり, 花田和彦
その他
準備中